Tissue Distribution of Radioactivity after Intravenous and Oral Administration of [14C]Brincidofovir to Rats

Tippin, Tim

doi:10.26226/morressier.57ea3d6ad462b8028d88ec64

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the relationship between peak HHV-6B DNA detection in blood and clinical outcomes, wherein viral loads higher than 10 000 copies/mL are sensitive and specific for HHV-6B encephalitis, 20,21 prophylactic brincidofovir could mitigate HHV-6B-associated complications. The high in vitro activity of brincidofovir for HHV-6B, 17 coupled with evidence for central nervous system penetration in animal models, 18,23 make it a promising candidate for prevention and treatment of HHV-6B.…”

Section: Resultsmentioning

confidence: 99%

Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT

Hill

Nichols

Marty

et al. 2020

Blood

View full text Add to dashboard Cite

Human herpesvirus 6B (HHV-6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT). There are no randomized studies of antiviral treatments to prevent HHV-6B reactivation. Brincidofovir has high in vitro activity against HHV-6B and other DNA viruses, but its in vivo activity for HHV-6B has not been demonstrated. We performed a post hoc analysis of a randomized controlled trial of twice-weekly oral brincidofovir for cytomegalovirus prophylaxis after allogeneic HCT to study the effect of brincidofovir on HHV-6B reactivation. We included patients randomized within 2 weeks of HCT and who received at least 6 consecutive doses of study drug after randomization. We tested plasma for HHV-6B through week 6 post-HCT. The cohort consisted of 92 patients receiving brincidofovir and 61 receiving placebo. The cumulative incidence of HHV-6B plasma detection through day 42 post-HCT was significantly lower among patients receiving brincidofovir (14.2%) compared with placebo (32.4%; log-rank, 0.019). In an adjusted Cox model, brincidofovir exposure remained associated with a lower hazard for HHV-6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80). In conclusion, brincidofovir prophylaxis reduced HHV-6B reactivation after allogeneic HCT in a post hoc analysis of a randomized controlled trial. These data support the study of intravenous brincidofovir for HHV-6B prophylaxis.

show abstract